Month: May 2026
From Biologics to Gene Therapy: A Conversation with Jim McNally
Overview Carolina Molecular recently sat down with Jim McNally of Sword Bio to discuss his path from the Gulf Coast of Mississippi into biotech and drug development, the evolution of CRO partnerships, and the increasing complexity of modern therapeutics. Throughout the conversation, Jim shares perspectives shaped by years of experience across academia, pharma, biotech, and…
How CRO Partnerships Accelerate Biologic Drug Development
How CRO Partnerships Accelerate Biologic Drug Development Biologic drug development is inherently complex. Unlike small molecules, biologics—monoclonal antibodies, fusion proteins, cytokines, gene therapies, and other advanced modalities—require highly specialized analytical characterization, immunogenicity assessment, and regulatory rigor. Internal teams at biotechnology companies often operate with lean headcount and limited infrastructure. As a result, strategic partnerships with…
Bioanalytical Challenges in Cell and Gene Therapy Products
Bioanalytical Challenges in Cell and Gene Therapy Products Cell and gene therapies (CGTs) represent one of the fastest-growing and most scientifically demanding areas of modern medicine. Unlike traditional small molecules or standard biologics, CGT products introduce living cells, viral vectors, nucleic acids, and genetically engineered constructs into patients. These therapies can produce durable, sometimes curative…
Sword Bio Appoints John Moriarity as Vice President, Business Development, East Coast
Sword Bio (“Sword”), a contract research organization that supports biotech and pharmaceutical companies with their bioanalytical needs for pre-clinical and clinical trials, announces the appointment of John Moriarity VP, Business Development, East Coast. John brings more than 20 years of biopharma experience to Sword Bio, with a career that began in the laboratory and evolved…